Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells
In Vivo · 2026-11 · 40 (6) · 3504-3518
DOI: 10.21873/invivo.14493 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Lipeng Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Intervention, the Second People's Hospital of Wuhu, Wuhu, P.R. China; xlp1393@163.com. Hauptthemen laut MEDLINE: Sorafenib, MicroRNAs, Hyaluronan Receptors, Carcinoma, Hepatocellular. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Intervention, the Second People's Hospital of Wuhu, Wuhu, P.R. China; xlp1393@163.com.
- Department of Tumor Intervention, the Second People's Hospital of Wuhu, Wuhu, P.R. China.
- Department of Medical Oncology, the First Affiliated Hospital of Wannan Medical College, Wuhu, P.R. China zwy815@126.com.
Zitieren
APA
Xu, L., Qin, L., & Zhao, W. (2026). Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells. In Vivo, 40(6), 3504-3518. https://doi.org/10.21873/invivo.14493
Vancouver
Xu L, Qin L, Zhao W. Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells. In Vivo. 2026;40(6):3504-3518. doi:10.21873/invivo.14493
BibTeX
@article{Xu2026,
author = {Xu, Lipeng and Qin, Ling and Zhao, Wenying},
title = {Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells},
journal = {In Vivo},
year = {2026},
volume = {40},
number = {6},
pages = {3504--3518},
doi = {10.21873/invivo.14493}
}
EUVIMED